Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1–42 antibodies in Alzheimer's disease patients
Authors:
- Elisa ContiECElisa Conti
- Gloria GalimbertiGGGloria Galimberti
- Lucio TremolizzoLTLucio Tremolizzo
- Alessandro MasettoAMAlessandro Masetto
- Diletta CeredaDCDiletta Cereda
- Clara ZanchiCZClara Zanchi
- Fabrizio PiazzaFPFabrizio Piazza
- Marco CasatiMCMarco Casati
- Valeria IsellaVIValeria Isella
- Ildebrando AppollonioIAIldebrando Appollonio
- Carlo FerrareseCFCarlo Ferrarese
- 17 December 2010
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 486 (3) , 193-196
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Increased Soluble APPα, Abeta 1-42, and Anti-Abeta 1-42 Antibodies in Plasma From Down Syndrome PatientsAlzheimer Disease & Associated Disorders, 2010
- Dissociated amyloid-β antibody levels as a serum biomarker for the progression of Alzheimer’s disease: A population-based studyExperimental Gerontology, 2010
- Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's diseaseProceedings of the National Academy of Sciences, 2009
- Antigen–antibody dissociation in Alzheimer disease: a novel approach to diagnosisJournal of Neurochemistry, 2008
- Catalytic antibodies to amyloid β peptide in defense against Alzheimer diseaseAutoimmunity Reviews, 2008
- Protective effect of donepezil against Aβ(1-40) neurotoxicity in rat septal neuronsBrain Research, 2005
- Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell linesJournal of Neurochemistry, 2004
- Immune response to Aβ-peptides in peripheral blood from patients with Alzheimer's disease and control subjectsNeuroscience Letters, 2004
- GalantamineDrugs, 2000
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984